**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Faizi Jamal, City of Hope National Medical Center, Duarte, California.

**Main Body of the Abstract**
Introduction:   In systemic light chain amyloidosis, and specifically cardiac amyloidosis, monoclonal light chain fibrils infiltrate the myocardium. Early detection and treatment of amyloidosis allows for arrest of fibril deposition and improved outcomes.  Echocardiography is a useful diagnostic modality for cardiac amyloidosis. While increased left ventricular (LV) wall thickness and reduced LV global longitudinal strain are classic echocardiographic findings in cardiac amyloidosis, we explored the utility of changes in 2-dimensional left atrial (LA) and right ventricular (RV) strain as early markers of cardiac amyloidosis.
Methods:  150 patients were retrospectively evaluated from our institutional multiple myeloma and amyloidosis registry. We identified 50 patients with AL amyloidosis and overt cardiac involvement (CA), 50 patients with AL amyloidosis and no suspected cardiac disease (AL), and 50 patients with multiple myeloma without amyloidosis (MM). Three experienced cardiologists were recruited for retrospective review of echocardiography. The list of 150 patients was shuffled and investigators were blinded to diagnosis.
Results:   Echocardiography for 48 patients with CA and 41 with AL were compared to a control group of 43 patients with MM. Results are presented in Table 1.
Conclusion:  We report significant change in cardiac anatomy and multiple parameters of atrial and ventricular function in patients with cardiac amyloidosis. We did not detect a difference in these measures when comparing patients with AL amyloidosis without cardiac involvement to patients with MM. Our findings suggest that novel echocardiographic parameters such as LA and RV strain may serve as powerful markers of cardiac amyloidosis.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Faizi Jamal, City of Hope National Medical Center, Duarte, California.

**Main Body of the Abstract**
**Introduction:**   In systemic light chain amyloidosis, and specifically cardiac amyloidosis, monoclonal light chain fibrils infiltrate the myocardium. Early detection and treatment of amyloidosis allows for arrest of fibril deposition and improved outcomes.  Echocardiography is a useful diagnostic modality for cardiac amyloidosis. While increased left ventricular (LV) wall thickness and reduced LV global longitudinal strain are classic echocardiographic findings in cardiac amyloidosis, we explored the utility of changes in 2-dimensional left atrial (LA) and right ventricular (RV) strain as early markers of cardiac amyloidosis.
**Methods:**  150 patients were retrospectively evaluated from our institutional multiple myeloma and amyloidosis registry. We identified 50 patients with AL amyloidosis and overt cardiac involvement (CA), 50 patients with AL amyloidosis and no suspected cardiac disease (AL), and 50 patients with multiple myeloma without amyloidosis (MM). Three experienced cardiologists were recruited for retrospective review of echocardiography. The list of 150 patients was shuffled and investigators were blinded to diagnosis.
**Results**:   Echocardiography for 48 patients with CA and 41 with AL were compared to a control group of 43 patients with MM. Results are presented in Table 1.
**Conclusion**:  We report significant change in cardiac anatomy and multiple parameters of atrial and ventricular function in patients with cardiac amyloidosis. We did not detect a difference in these measures when comparing patients with AL amyloidosis without cardiac involvement to patients with MM. Our findings suggest that novel echocardiographic parameters such as LA and RV strain may serve as powerful markers of cardiac amyloidosis.



Diagnostic utility of left atrial and right ventricular strain analyses in patients with AL amyloidosis PB107 (#244)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.